Blog
RSS FeedPosted by Michael Wonder on 07 Oct 2025
Jesse's dad, who walked Canada for his son, cheers approval of new Duchenne drug
3 October 2025 - Vamorolone is the first Health Canada approved drug developed specifically to treat Duchenne. ...
Posted by Michael Wonder on 03 Oct 2025
Health Canada approves Agamree (vamorolone) as the first treatment for Duchenne muscular dystrophy in Canada
2 October 2025 - Kye Pharmaceuticals announced today that Health Canada has approved Agamree (vamorolone) for the treatment of Duchenne muscular ...
Posted by Michael Wonder on 02 Oct 2025
Organon Canada announces the availability of Nduvra (1% tapinarof cream) for the topical treatment of plaque psoriasis in adults
1 October 2025 - Organon Canada announces the availability of Ndruvra (1% tapinarof cream) for the topical treatment of plaque psoriasis ...
Posted by Michael Wonder on 24 Sep 2025
Teva and Medincell’s risperidone LAI approved in Canada as Longavo
23 September 2025 - Teva Canada has received regulatory approval for risperidone long-acting injection from Health Canada for the treatment ...
Posted by Michael Wonder on 21 Sep 2025
Moderna produces its first Canadian mRNA vaccines in its new state of the art Quebec facility
19 September 2025 - Today, the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for ...
Posted by Michael Wonder on 20 Sep 2025
Health Canada approves Celltrion’s Stoboclo and Osenvelt (CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia and Xgeva, respectively
18 September 2025 - The approval is based on the totality of evidence including results from a Phase III clinical ...
Posted by Michael Wonder on 11 Sep 2025
Health Canada approves Slenyto - extended-release melatonin formulation - as a prescription drug for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome
10 September 2025 - Neurim Pharmaceuticals is pleased to announce that Health Canada has granted marketing authorisation for Slenyto, an ...
Posted by Michael Wonder on 10 Sep 2025
Alberta man pushes Feds to approve new Alzheimer’s drugs Leqembi and Kinsula
9 September 2025 - An Alberta man living with Alzheimer’s disease is calling on Ottawa to approve two new drugs ...
Posted by Michael Wonder on 10 Sep 2025
Health Canada approves Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome
9 Settember 2025 - Bylvay is the first and only medication approved in Canada for the treatment of both Alagille ...
Posted by Michael Wonder on 06 Sep 2025
Sol-Gel announces Health Canada approval of Epsolay
4 September 2025 - - Sol-Gel Technologies announced today that on 27 August 2 2025 Health Canada issued a Notice ...
Posted by Michael Wonder on 03 Sep 2025
Health Canada approves Elahere for certain types of platinum-resistant ovarian cancers
2 September 2025 - Elahere received approval through Health Canada's priority review process, based on data from the pivotal MIRASOL Phase ...
Posted by Michael Wonder on 28 Aug 2025
Rinvoq (upadacitinib) receives Health Canada notice of compliance for giant cell arteritis in adults
27 August 2025 - This marks the eighth approved indication for Rinvoq in Canada across rheumatology, gastro-enterology and dermatology. ...
Posted by Michael Wonder on 27 Aug 2025
Leo Pharma announces Health Canada approval of Anzupgo for treatment of moderate to severe chronic hand eczema
26 August 2025 - Approval was based on results from the DELTA 1 and 2 trials, which evaluated the safety and ...
Posted by Michael Wonder on 25 Aug 2025
Moderna receives Health Canada approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1
22 August 2025 - All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone. ...
Posted by Michael Wonder on 25 Aug 2025
Health Canada approves Roche’s Columvi (glofitamab) as the first bi-specific antibody in Canada for relapsed or refractory diffuse large B-cell lymphoma after initial therapy
21 August 2025 - Approval is based on Phase 3 STARGLO study where Columvi in combination with chemotherapy showed a ...